Femoxetine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Femoxetine
Femoxetine.png
Systematic (IUPAC) name
(3R,4S)-3-[(4-methoxyphenoxy)methyl]-1-methyl-4-phenyl-piperidine
Clinical data
  • Uncontrolled
Oral
Pharmacokinetic data
Half-life 7-27 hours
Identifiers
59859-58-4
None
PubChem CID 3012003
ChemSpider 2280941 YesY
UNII 8Y719ZLX8C YesY
ChEMBL CHEMBL94739 YesY
Chemical data
Formula C20H25NO2
311.42 g/mol
 YesY (what is this?)  (verify)

Femoxetine (Malexil, FG-4963) is a drug related to paroxetine that was being developed as an antidepressant by Danish pharmaceutical company Ferrosan in 1975 before acquisition by Novo Nordisk. It functions as a selective serotonin reuptake inhibitor (SSRI). Development was halted to focus attention on paroxetine instead, given femoxetine's inability to be administered as a daily pill.

Both femoxetine and paroxetine were invented in the 1970s by Jorgen Buus-Lassen (Jørgen Anders Christensen name on the patents though).[1][2] After Ferrosan's acquisition, femoxetine died from neglect.[3]

References[edit]

  1. ^ U.S. Patent 3,912,743
  2. ^ U.S. Patent 4,007,196
  3. ^ Healy, David (2004). Let them eat Prozac : the unhealthy relationship between the pharmaceutical industry and depression. New York, NY: New York Univ. Press. pp. 26–27. ISBN 9780814736692.